Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Mutlu Hizal"'
Autor:
Mutlu Hizal, Abdurrahman Tufan, Ridvan Mercan, Ozge Tugce Pasaoglu, Hatice Pasaoglu, Seminur Haznedaroglu, Berna Goker, Mehmet Akif Ozturk
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-5 (2024)
Abstract In a previous study, it has been shown that the population of Th17 lymphocytes was increased in patients with FMF. IL-21 and IL-23 play significant roles in the production and differentiation of Th17 cells. In this study, we aimed to evaluat
Externí odkaz:
https://doaj.org/article/b9be49d5a1444b0bb45ec87d63d63c35
Publikováno v:
Ankara Medical Journal, Vol 19, Iss 4, Pp 729-735 (2019)
Giriş: İnflamasyon kanser gelişimini kolaylaştırmanın yanı sıra birçok kanser tipinde kötü prognozla da ilişkilidir. Albümin ve globülin inflamasyonu yansıtan belirteçlerden ikisidir. Albüminin özellikle inflamasyon dışı birçok
Externí odkaz:
https://doaj.org/article/95bb7a8461dd40799340fafe56c7ad2c
Autor:
Burak Bilgin, Mehmet AN. Sendur, Mutlu Hizal, Sümeyye Ulutas Kandil, Samet Yaman, Muhammed Bülent Akıncı, Didem Şener Dede, Salim Neselioglu, Özcan Erel, Bülent Yalçın
Publikováno v:
Journal of Oncological Sciences, Vol 5, Iss 2, Pp 60-64 (2019)
Aim: Data about the relationship between oxidative stress and cancer pathogenesis has been increased in recent years. Thiol and disulphide play an important role in cell signal mechanisms, antioxidant protection, and detoxification. In this study, we
Externí odkaz:
https://doaj.org/article/b8bf8949e77d4e11827432caa59a2406
Autor:
Mutlu Hizal, Mehmet A.N. Sendur, Burak Bilgin, Muhammed Bulent Akinci, Didem Sener Dede, Salim Neselioglu, Ozcan Erel, Bulent Yalcin
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 1, Pp 1-4 (2018)
Background: Gastric cancer is one the most diagnosed cancer and the third leading cause of death from cancer worldwide. As an indicator of antioxidant capacity thiol/disulfide homeostasis regulates detoxification, cell signal mechanisms, apoptosis, t
Externí odkaz:
https://doaj.org/article/467467e5c6164620af60b80ff161ba09
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Saadettin Kılıçkap, Muhammed Mustafa Atcı, Seda Kahraman, Merve Keskinkılıç, İrem Bilgetekin, Murat Ayhan, Deniz Tural, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ali Murat Tatlı, Ertuğrul Bayram, Yasin Kutlu, İsmail Ertürk, Erkan Özcan, Ahmet Gülmez, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Yakup İriağaç, Naziyet Köse Baytemür, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Fatih Selçukbiricik, Yakup Ergün, Taner Korkmaz, Naziye Ak, Çağlar Ünal, Nadiye Akdeniz, Mehmet Alpaslan Özgün, Berna Öksüzoğlu, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Publikováno v:
Future Oncology. 18:2573-2582
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043d1a22a8f3e83e986a7039a57bac7a
https://doi.org/10.2217/fon-2022-0083
https://doi.org/10.2217/fon-2022-0083
Autor:
Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran, Semra Paydas, Arzu Yaren, Deniz Can Guven, Atike Pinar Erdogan, Umut Demirci, Alper Yasar, İbrahim Vedat Bayoglu, Mutlu Hizal, Burcu Gulbagci, Nail Paksoy, Sena Ece Davarci, Funda Yilmaz, Ozlem Dogan, Sibel Oyucu Orhan, Erkan Kayikcioglu, Ali Aytac, Merve Keskinkilic, Eda Eylemer Mocan, Olcun Umit Unal, Esra Aydin, Hakan Yucel, Deniz Isik, Onder Eren, Basak Oyan Uluc, Melike Ozcelik, Ilhan Hacibekiroglu, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Ebru Cilbir, Erdem Cubukcu, Bulent Cetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgun Yildirim, Ali Alkan, Fatih Selcukbiricik, Asude Aksoy, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Dincer Aydin, Ozgecan Dulgar, Muhammed Muhiddin Er, Fatih Teker, Tugba Yavuzsen, Musa Baris Aykan, Ali Inal, Yakup Iriagac, Nurhan Onal Kalkan, Murat Keser, Teoman Sakalar, Serkan Menekse, Engin Kut, Burak Bilgin, Muge Karaoglanoglu, Veli Sunar, Ozlem Ozdemir, Nazim Serdar Turhal, Nuri Karadurmus, Bulent Yalcin, Mehmet Ali Nahit Sendur
Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af4603b0dea982cdc71feb0666817cb5
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
https://avesis.deu.edu.tr/publication/details/6b4454d1-de76-4c63-9dab-2c0deccc7b07/oai
Autor:
Mutlu HIZAL, Mehmet Ali Nahit ŞENDUR, Burak BİLGİN, Ebru KARCI GÜNER, Muhammed Bülent AKINCI, Yakup ERGÜN, Ece ESİN, Elif Berna KÖKSOY, Ahmet SEZER, Nuriye ÖZDEMİR, Berna ÖKSÜZOĞLU, Bülent YALÇIN, Güngör UTKAN, Yüksel ÜRÜN
Publikováno v:
Journal of Oncological Sciences. 8:69-75
ABS TRACT Objective: Pancreatic cancer is one of the leading causes of cancer-related death. Despite the introduction of new therapeutic agents, survival rates remain low. Furthermore, few trials have evaluated the options for second-line therapy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb55beeaf8886980bb0bc1428a235c69
https://doi.org/10.37047/jos.2022-88853
https://doi.org/10.37047/jos.2022-88853
Autor:
Sadettin Kilickap, Mutlu Hizal, Ahmet Gulmez, Okan Avci, Burak Yasin Aktas, Havva Yesil Cinkir, Emir Celik, Mustafa Gürbüz, Berna Oksuzoglu, Ali Murat Tatli, Gulhan Ipek Deniz, Cihan Erol, Erdem Sen, Fulden Yumuk, A İlhan, Şebnem Yücel, Semra Paydas, Ozkan Alan, Engin Kut, Fatih Karatas, Atakan Demir, Murat Ayhan, Bulent Yalcin, Halil Taskaynatan, Tugba Basoglu, Serkan Menevse, Deniz Tataroğlu Özyükseler, Nadiye Akdeniz, Sinan Koca, Mustafa Karaagac, Burak Bilgin, Didem Sener Dede, Mehmet Ali Nahit Sendur, Muhammed Bulent Akinci, Izzet Dogan, Ahmet Demirkazik, Teoman Sakalar
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2145-2152
The new second-generation tyrosine kinase inhibitors (TKIs) have superior survival outcome and worse toxicity profile when compared with first-generation TKIs according to the results of clinical trials. However, there are limited studies that invest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d89c7618b60463a480bb0c32d1d2ee
https://doi.org/10.1007/s00432-020-03501-6
https://doi.org/10.1007/s00432-020-03501-6
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Muhammed Mustafa Atcı, Seda Kahraman, Saadettin Kılıçkap, Merve Keskinkılıç, Murat Ayhan, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ertuğrul Bayram, İsmail Ertürk, Erkan Özcan, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Naziyet Köse Baytemür, Ahmet Gülmez, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Ali Murat Tatlı, Yakup Ergün, Naziye Ak, Çağlar Ünal, Mehmet Alpaslan Özgün, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb3cc0c537f79435ee24f92ba6ab7f9b
https://doi.org/10.21203/rs.3.rs-1583429/v1
https://doi.org/10.21203/rs.3.rs-1583429/v1
Autor:
Kadriye Bir Yucel, Umut Demirci, Hatime Arzu Yasar, Yuksel Urun, Burak Bilgin, Mehmet An Şendur, Hakan Taban, Bulent Yalcin, Nuri Karadurmus, Cagatay Arslan, Gokhan Ucar, Serdar Karakaya, Nuriye Yildirim, Ismail Erturk, Irfan Cicin, Ahmet Kucukarda, Saadettin Kilickap, Mutlu Hizal
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1583-1589
Background To describe the prognostic value of neutrophil–lymphocyte ratio and its effect on survival in in patients with advanced renal cell carcinoma. Methods We retrospectively analyzed 331 patients. The cut-off value of neutrophil–lymphocyte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cedf56b5fd9cd8a480ef474f54f9acd4
https://doi.org/10.1177/1078155219900908
https://doi.org/10.1177/1078155219900908